October 27, 2021 7:54am
After a six (6) sector stumbles out of seven (7) sessions, the probabilities of some upside are still relative
Pre-open indications: 4 SELLs, 1 BUY and with 1 Pump (or No Promote)
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.06% (+20 points), S&P futures are DOWN -0.03% (-1 point) and NASDAQ futures are DOWN -0.05% (-8 point)
U.S. stock index futures were mixed, falling and skinny during early morning trading on Wednesday,
European stocks were slightly lower after a budget update from the U.K. finance minister,
Asia Pacific shares were lower with Chinese tech stocks in Hong Kong seeing big losses.
Henry’omics:
Indexes rally opened strongly but pared gains, then wiping out gains or turning slightly negative before ending slightly positive.
The Dow closed +0.04%; the S&P 500 index rose 0.2% while the Nasdaq rose +0.06% and the small-cap Russell 2000 fell -0.7% in Tuesday's stock market trading.
Economic data Docket: U.S. durable goods order data will be released at 8:30 a.m. ET.
If you didn’t remember what happen at Tuesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
- Tuesday’s evening’s recap: “taking profits as sector equities descend the down sliding sector. Pre earnings releases progresses share pricing squeezes.” … https://www.regmedinvestors.com/articles/12155
Q4: October, 7 positive and 11 negative closes
Q3/21:
- September, 1 holiday, 10 positive and 10 negative close
- August - 12 positive and 10 negative close
- July: 6 positives, 1 holiday and 15 negative closes
Companies in my headlights – It’s your decision; I provide an idea and context:
SELL with a Pump or no promote:
Biostage (BSTG) closed down -$0.05 with 1,216 shares traded after Monday’s flat at $3.05 with 609 shares traded, Friday’s -$0.156 with 516 shares traded, Thursday’s -$0.095 with 265 shares traded, and last Wednesday’s +$0.30 with 8,356 shares traded.
- For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.
- What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
Maintaining SELL for profit:
bluebird bio (BLUE) closed down -$0.28 to $20.95 after Monday’s +$0.43, Friday’s +$0.41 to $20.80 and Thursday’s -$0.59 with a positive +$0.05 or +0.24% pre-open indication.
SELL:
Cellectis SA (CLLS) closed down -$0.08 to $10.78 with a negative -$0.14 or -1.30% aftermarket indication.
Mesoblast (MESO) closed down -$0.06 to $6.24 with a negative -$0.17 or -2.73% aftermarket indication.
Maintaining Sell into Strength:
BioLife Solutions (BLFS) closed up +$1.99 to $47.27 after Monday’s +$2.28 to $45.28, Friday’s +$0.01 and Thursday’s +$0.54 and last Wednesday’s +$0.38 with NO pre-open indication.
BUY:
uniQure NV (QURE) closed down -$0.98 to $28.38 after Monday’s +$0.90 to $29.36, Thursday’s -$0.23 with a positive +$0.17 or +0.60% pre-open indication after reporting a net loss of -$36.5 M or -$0.79 per shares, a small +$200 K upload of revenue from Q2, $578.5 M in cash and a runway until 1H/24.
The BOTTOM LINE: Reiterating, “Don't let earnings week take advantage of you” … because it will!
Be ready to act on up-coming earnings news, good or bad, but don't be too hasty.
It's highly risky to buy a stock just before earnings, and investors may want to take whole or partial profits on holdings with tiny gains.
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
The stem, cell and gene therapy earnings with Alnylam Pharmaceuticals on 10/28, Sage Therapeutics (SAGE), Ultragenyx Pharmaceuticals (RARE) and Regenxbio (RGNX) on 11/2, Editas medicine (EDIT) on 11/8, Vericel (VCEL) on 11/9, Athersys ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date).
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
